Originally developed by a research team at Washington State University in the United States, Dihexa is classified as an Angiotensin IV analog, yet it possesses a significantly more potent capacity for synaptogenesis (the formation of new synapses)
Composition AOD 9604: 5 mg Appearance: Lyophilized powder in a sealed research vial Research Focus (non-clinical) Peptide identity and purity assessment via HPLC/LC-MS Assay development and calibration for quantitative analysis Chromatographic method optimization for impurity profiling Stability characterization of a lyophilized peptide under laboratory storage conditions Documentation COA pending third-party verification in progress Important Notice For research use only Not for human consumption Not intended to diagnose, treat, cure, or prevent any disease Quality & Manufacturing Lot-specific COA (HPLC/LC-MS) with verification key Third-party verification link provided per lot (Janoshik) Lyophilized for transit stability
To avoid denials, its essential to follow coding best practices and ensure all documentation is thorough and complete
Practical stacking protocols Translating synergy theory into practical protocols requires attention to dosing, timing, duration, and administration methods
It has also gained attention for its exercise-mimetic properties